Role of mitochondria in SLE and its cardiovascular complications
线粒体在 SLE 及其心血管并发症中的作用
基本信息
- 批准号:10274520
- 负责人:
- 金额:$ 60.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-25 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AerobicAffinityAnaerobic BacteriaAntibodiesAnticardiolipin AntibodiesAntigensAntiphospholipid SyndromeAutoantibodiesAutoantigensAutoimmunityBiological MarkersBiologyBlood PlateletsCardiolipinsCardiovascular DiseasesCardiovascular systemCellsCessation of lifeClinicalCoagulation ProcessComplementComplement 1qDataDevelopmentDiseaseDisease ManagementEarly treatmentEngineeringExcisionExposure toFlow CytometryGenomeImmuneImmune responseImpairmentIn VitroIndividualInflammationInflammatoryLifeLupusMass Spectrum AnalysisMediatingMethionineMitochondriaMitochondrial ProteinsModelingMonitorMusOrganOutcomeOutcome MeasurePathologyPathway interactionsPatientsPhagocytosisPhospholipidsPlatelet ActivationPower PlantsPreventive measurePreventive treatmentProcessProductionPrognostic MarkerProkaryotic CellsPropertyProtein BiosynthesisReactive Oxygen SpeciesResearchRheumatoid ArthritisRiskRoleSamplingSignal PathwaySystemSystemic Lupus ErythematosusTestingThrombosisThrombusVenous ThrombosisWorkbasecohortcomplement systemcytokinedesignexperimental studyextracellularhuman diseaseimmunogenicin vivoin vivo Modelinsightmouse modelneutrophilnew therapeutic targetnovelnovel markerphosphoproteomicsprognostictherapeutic targetvenous thromboembolism
项目摘要
Summary: Upon cellular death, cells release damaged mitochondria, contributing to local
inflammation. The overall aims of the present study are to investigate how mitochondria are
cleared to avoid evoking an aberrant immune response, and to determine if autoantibodies
targeting mitochondrial proteins have clinical utility in assessing development of thrombosis in
patients with systemic lupus erythematosus (SLE). The premise of the study is that SLE patients
have impaired clearance of mitochondria, promoting development of mitochondrial antibodies,
inflammation and organ damage, including thrombosis. To investigate this we have three main
aims. The first aim investigates how mitochondrial extrusion promotes autoimmunity towards
mitochondrial protein antigens, attempting to define the exact target of novel main mitochondrial
autoantibody, AMA-17, the processes involved in exposing the autoantigen in vitro, as well as
potential therapeutic targets, e.g. mitochondrial ROS, involved in generating AMA-17 in vivo.
The second aim investigates how anti-mitochondrial antibodies partake in thrombosis
development. Using a large longitudinal SLE cohort (n=500), followed over 10 years, we will
determine the capacity of AMA-17 to associate with and/or predict development of venous
thrombosis. Affinity-purified AMA-17 antibodies will be tested for platelet activation and
thrombus formation in vitro using flow cytometry, aggregometry and a cutting-edge model of
engineered microvessels, as well as in vivo using a novel model of antibody-mediated venous
thrombosis developed by Dr. Knight. Finally, in Aim 3, we will investigate underlying
mechanisms involved in clearance of mitochondria, with an emphasis on the role of complement
C1q and C3 to facilitate silent clearance. These studies will be done both in vitro using select
isolated complement components, as well as in vivo using unique C1q and C3 deficient mice.
Outcome measures include phagocytosis, cytokine production, and NET formation.
Downstream signaling pathways involved in mitochondrial-mediated inflammation will be
identified using mass spectrometry-based phosphoproteomics. In all, our study aims at
identifying fundamental mechanisms regulating inflammation, thrombosis and autoimmunity in
the context of human disease, with an emphasis on the role of the complement system in silent
removal of mitochondria. We expect the proposed research to provide novel therapeutic targets
disrupting the inflammatory and immunogenic properties of mitochondria, applicable for many
diseases, including SLE and rheumatoid arthritis, as well as identify prognostic mitochondrial-
derived biomarkers enabling early and preventive treatment of venous thrombosis.
摘要:细胞死亡后,细胞释放受损的线粒体,有助于局部
炎。本研究的总体目标是研究线粒体如何
清除以避免引起异常免疫反应,并确定自身抗体是否
靶向线粒体蛋白在评估血栓形成的发展方面具有临床实用性
系统性红斑狼疮 (SLE) 患者。该研究的前提是 SLE 患者
线粒体清除受损,促进线粒体抗体的形成,
炎症和器官损伤,包括血栓形成。为了调查这个问题,我们有三个主要的
目标。第一个目标是研究线粒体挤压如何促进自身免疫
线粒体蛋白抗原,试图定义新型主要线粒体的确切靶标
自身抗体,AMA-17,体外暴露自身抗原的过程,以及
潜在的治疗目标,例如线粒体 ROS,参与体内生成 AMA-17。
第二个目标是研究抗线粒体抗体如何参与血栓形成
发展。通过使用大型纵向 SLE 队列(n=500)并跟踪 10 多年,我们将
确定 AMA-17 关联和/或预测静脉发育的能力
血栓形成。将测试亲和纯化的 AMA-17 抗体的血小板活化和
使用流式细胞术、聚集测量法和尖端模型体外血栓形成
工程微血管,以及体内使用抗体介导的静脉的新型模型
奈特博士开发的血栓形成。最后,在目标 3 中,我们将研究潜在的
涉及线粒体清除的机制,重点是补体的作用
C1q和C3便于无声通关。这些研究将在体外使用选择进行
分离补体成分,以及在体内使用独特的 C1q 和 C3 缺陷小鼠。
结果指标包括吞噬作用、细胞因子产生和 NET 形成。
参与线粒体介导的炎症的下游信号通路将是
使用基于质谱的磷酸蛋白质组学进行鉴定。总而言之,我们的研究目的是
确定调节炎症、血栓形成和自身免疫的基本机制
人类疾病的背景,重点是补体系统在沉默中的作用
去除线粒体。我们期望拟议的研究能够提供新的治疗靶点
破坏线粒体的炎症和免疫原性,适用于许多
疾病,包括系统性红斑狼疮和类风湿性关节炎,以及确定预后线粒体
衍生的生物标志物能够对静脉血栓形成进行早期和预防性治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jan Christian Lood其他文献
Jan Christian Lood的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jan Christian Lood', 18)}}的其他基金
Role of mitochondria in SLE and its cardiovascular complications
线粒体在 SLE 及其心血管并发症中的作用
- 批准号:
10473713 - 财政年份:2021
- 资助金额:
$ 60.89万 - 项目类别:
Extracellular mitochondria in Inclusion Body Myositis
包涵体肌炎的细胞外线粒体
- 批准号:
10282390 - 财政年份:2021
- 资助金额:
$ 60.89万 - 项目类别:
Role of mitochondria in SLE and its cardiovascular complications
线粒体在 SLE 及其心血管并发症中的作用
- 批准号:
10652483 - 财政年份:2021
- 资助金额:
$ 60.89万 - 项目类别:
Mitochondrial calcification in juvenile dermatomyositis
幼年皮肌炎的线粒体钙化
- 批准号:
10245228 - 财政年份:2020
- 资助金额:
$ 60.89万 - 项目类别:
Investigating how platelet-derived growth factor receptors direct synovialfibroblast-mediated pathology in inflammatory arthritis
研究血小板衍生生长因子受体如何指导炎症关节炎中滑膜成纤维细胞介导的病理学
- 批准号:
10260607 - 财政年份:2020
- 资助金额:
$ 60.89万 - 项目类别:
Investigating how platelet-derived growth factor receptors direct synovialfibroblast-mediated pathology in inflammatory arthritis
研究血小板衍生生长因子受体如何指导炎症关节炎中滑膜成纤维细胞介导的病理学
- 批准号:
10247966 - 财政年份:2020
- 资助金额:
$ 60.89万 - 项目类别:
Mitochondrial calcification in juvenile dermatomyositis
幼年皮肌炎的线粒体钙化
- 批准号:
10027222 - 财政年份:2020
- 资助金额:
$ 60.89万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 60.89万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 60.89万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 60.89万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 60.89万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 60.89万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 60.89万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 60.89万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 60.89万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 60.89万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 60.89万 - 项目类别:
Continuing Grant